Halozyme Therapeutics, Inc. (NASDAQ: HALO) has recently announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals. This partnership grants Acumen access to Halozyme's ENHANZE® drug delivery technology, which utilizes a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for efficient subcutaneous drug delivery. The collaboration is focused on a single target, as Acumen aims to investigate the potential use of ENHANZE® for ACU193, Acumen's clinical-stage monoclonal antibody (mAb) candidate designed to target Amyloid-β Oligomers (AβOs) for the treatment of early Alzheimer's disease (AD).

According to the terms of the agreement, Acumen will make an initial payment to Halozyme, along with potential future milestone payments linked to development progress, regulatory approvals, and sales achievements. Halozyme will also be entitled to single-digit royalties based on net sales of medicines that utilize the ENHANZE® technology.

This collaboration presents a significant opportunity to expand the range of treatment options available to patients with Alzheimer's disease. As per the World Health Organization, more than 55 million people worldwide are affected by dementia, with Alzheimer's disease accounting for 60-70% of these cases.

Acumen has reported positive Phase 1 results, indicating that ACU193 is generally well-tolerated and has a compelling overall safety profile. These results fulfill the primary objective of its first-in-human, randomized, double-blind, placebo-controlled study, involving both single and multiple doses administered to early AD patients. ACU193 has earned Fast Track designation from the U.S. Food and Drug Administration for the treatment of early Alzheimer's disease.

Halozyme, expressed her enthusiasm about the partnership with Acumen for ENHANZE, underscoring the commitment to delivering innovative solutions to enhance the treatment experience for patients, especially those dealing with such a challenging disease that affects a substantial patient population. She also noted that the Alzheimer's disease treatment landscape is undergoing a crucial transformation, with recent and anticipated approvals opening up new avenues for treatment. The company is eager to enter this market and support the development of ACU193 as a potential treatment option.

This agreement signifies Halozyme's thirteenth global collaboration and license partner for the ENHANZE® technology. These partnerships encompass over 60 therapeutic targets and have resulted in seven commercialized products to date.

 

Source: prnewswire.com

Report Abuse